Nuchal translucency measurement, freeβ-hCG and PAPP-A concentrations in IVF/ICSI pregnancies: systematic review and meta-analysis
- 29 May 2017
- journal article
- research article
- Published by Wiley in Prenatal Diagnosis
- Vol. 37 (6) , 540-555
Abstract
So far, data on the effect of assisted reproductive technologies (ART) on the components of first trimester combined screening for Down syndrome are still controversial. A systematic search of the literature was performed in order to identify the effect of ART, particularly in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) with fresh embryo transfer, on the nuchal translucency, free beta-human chorionic gonadotrophin and pregnancy-associated plasma protein-A measurements. Moreover, a meta-analysis and a descriptive graphical representation of the ratios between ART and spontaneous pregnancies (controls) values of median of the multiple of median (m0MoM) were performed. Free beta-human chorionic gonadotrophin test showed slightly higher values in the ICSI group than controls (RR = 1.09, 95%CI: 1.03–1.16) but not in the IVF group (RR = 1.03, 95%CI: 0.94–1.12). Pregnancy-associated plasma protein-A values for IVF/ICSI, IVF and ICSI showed lower values in comparison with controls (RR, 95%CI 0.85, 0.80–0.90; 0.82, 0.74–0.89 and 0.83, 0.79–0.86, respectively). The nuchal translucency measurement did not show any statistical differences between study groups (IVF and ICSI) and controls (RR = 1.00, 95%CI: 0.94–1.08 and RR = 1.01, 95%CI: 0.97–1.05, respectively). These results may be due to alterations in the placentation of ART pregnancies. Differentiating further subgroups of ART pregnancies may explain the differences in biomarker concentrations, in prenatal behavior and in obstetric outcomes between ART and spontaneous pregnancies. © 2017 John Wiley & Sons, Ltd.Keywords
This publication has 50 references indexed in Scilit:
- Prenatal Screening for Fetal Aneuploidy in Singleton PregnanciesJournal of Obstetrics and Gynaecology Canada, 2011
- A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessmentPrenatal Diagnosis, 2011
- Additional First-Trimester Ultrasound MarkersClinics In Laboratory Medicine, 2010
- First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markersPrenatal Diagnosis, 2010
- Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndromeHuman Reproduction, 2009
- First trimester screening for Down's syndrome after assisted reproductive technology: non-male factor infertility is associated with elevated free beta-human chorionic gonadotropin levels at 10–14 weeks of gestationFertility and Sterility, 2008
- First‐trimester screening for trisomy 21 by free beta‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A: impact of maternal and pregnancy characteristicsUltrasound in Obstetrics & Gynecology, 2008
- First trimester biochemical screening for Down's syndrome in singleton pregnancies conceived by assisted reproductionHuman Reproduction, 2005
- A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐AUltrasound in Obstetrics & Gynecology, 1999
- UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10–14 weeks of gestationThe Lancet, 1998